Key points are not available for this paper at this time.
This survey study examines how well physicians understand the US Food and Drug Administration’s (FDA’s) statutory definition of a “breakthrough” therapy, and whether the term breakthrough affects their perceptions of a drug’s efficacy.
Kesselheim et al. (Tue,) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: